The most common adverse events of dabrafenib and trametinib therapy for NSCLC have been reported to be pyrexia, elevated alanine aminotransferase levels, hypertension, anemia, a confused state, decreased appetite, hemoptysis, hypercalcemia, nausea, vomiting, neutropenia, hyponatremia, and a reduction in the ejection fraction.3, 4. The gene discussed is GPT; the disease is hypercalcemia disease.